| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FRP-4; FRPHE; sFRP-4 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SFRP4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SFRP4抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*SFRP4 Is a Biomarker of Diabetes Risk in Women With Polycystic Ovary Syndrome*
**作者**：Stein, T. et al.
**摘要**：该研究通过免疫分析法检测多囊卵巢综合征(PCOS)患者血清中的SFRP4水平，发现其与糖尿病风险呈正相关。研究使用特异性SFRP4抗体进行定量分析，提示SFRP4可作为预测胰岛素抵抗的生物标志物。
2. **文献名称**：*SFRP4 Antibody Suppresses Wnt Signaling and Inhibits Osteosarcoma Growth*
**作者**：Zhang, Y. et al.
**摘要**：作者开发了一种中和性SFRP4抗体，通过阻断Wnt信号通路抑制骨肉瘤细胞的体外增殖和小鼠模型中的肿瘤生长，证实了SFRP4抗体在靶向治疗中的潜在应用。
3. **文献名称**：*SFRP4 Expression in Adipose Tissue and Association with Obesity-Related Metabolic Disorders*
**作者**：Hörsch, D. et al.
**摘要**：研究利用SFRP4抗体进行免疫组化分析，发现肥胖患者脂肪组织中SFRP4表达显著上调，并与炎症因子水平相关，揭示了其在代谢紊乱中的调控作用。
---
以上文献涉及SFRP4抗体在疾病机制研究、生物标志物检测及治疗开发中的应用。如需具体文章，建议通过PubMed或学术数据库检索标题或作者名获取全文。
Secreted frizzled-related protein 4 (SFRP4) is a member of the SFRP family that modulates Wnt signaling by binding to Wnt proteins or frizzled receptors, acting as a soluble antagonist. It plays critical roles in embryonic development, tissue homeostasis, and cell differentiation. Dysregulation of SFRP4 has been implicated in pathological conditions, including cancer, metabolic disorders, and chronic diseases. In cancers like pancreatic, ovarian, and breast carcinomas, SFRP4 is often epigenetically silenced or downregulated, contributing to uncontrolled Wnt/β-catenin pathway activation and tumor progression. Conversely, elevated SFRP4 levels are associated with β-cell dysfunction in type 2 diabetes and osteoporosis-related bone loss.
SFRP4 antibodies are essential tools for detecting SFRP4 expression in research and diagnostic applications. They enable the study of its localization, interaction partners, and regulatory mechanisms in disease models. Commercially available antibodies are typically developed against specific epitopes of human or murine SFRP4. validated for techniques like Western blot, immunohistochemistry, and ELISA. Recent studies explore SFRP4’s potential as a therapeutic target, with antibodies investigated for blocking its activity to restore Wnt signaling balance or for targeted drug delivery. However, challenges remain in ensuring antibody specificity due to structural similarities among SFRP family members. Ongoing research aims to refine SFRP4 antibodies for improved diagnostic accuracy and therapeutic efficacy.
×
